Although still unsupported by clear translational evidence, the GLP1 RAs-induced upregulation of ACE2 could ameliorate lung injury during COVID-19, antagonizing the reduction of ACE2 expression levels that are hallmarks of infection progression [15,27] and preventing the over-activated immune response critical for ARDS [62]. The gene discussed is ACE2; the disease is COVID-19.